Skip to main content

Give us a call

Thank you for your interest in CSL. We care about your questions and concerns. You can find the best way to contact us from the list below.

CSL Parkville office

General Enquiries

CSL Limited Head Office

Phone: +61 3 9389 1911
Fax: +61 3 9389 1434

Submit general enquiries

Customer Service

Within Australia

Plasma-Derived Therapies

Phone: 1800 063 892

Pharmaceuticals and Vaccines

Phone: 1800 008 275

Outside Australia

CSL Seqirus

Phone: 1800 008 275

Media Enquiries

Australian Media Contact

Mobile: +61 0450 909 211
Email: (non-urgent enquires)

Country Contacts

CSL Behring

CSL Seqirus


Bernard Ronchi

CSL Limited Investor Relations
Phone: +61 3 9389 3470


The CSL share registry is managed and maintained by Computershare.
Phone: 1800 646 882
Outside Australia: +61 3 9415 4178
Fax: +61 3 9473 2500

Medical Information

Undesirable Effect Within Australia

CSL Behring Pharmaceuticals

Phone: 1800 642 865 (Toll Free within Australia)

CSL Seqirus Vaccines

Phone: 1800 642 865 (Toll Free within Australia)

Undesirable Effect Within New Zealand

CSL Behring Pharmaceuticals

Phone: 0800 640 677

CSL Seqirus Vaccines

Phone: 0800 502 757

Undesirable Effect Outside Australia & New Zealand

global contact

About CSL Seqirus

CSL Seqirus is the world’s No. 2 influenza vaccine provider in sales with operations in more than 20 countries in the US$4 billion global industry. CSL Seqirus provides a differentiated product portfolio, possesses strong pandemic and prepandemic franchises and manages one of the world’s largest influenza vaccine manufacturing networks with operations on three continents: North America, Europe and Australia.

CSL Behring King of Prussia

About CSL Behring

We are committed to saving lives and improving the quality of life for people with rare and serious diseases worldwide. This commitment is reflected in our support of therapies for people with deficient or malfunctioning blood proteins that cause diseases like bleeding disorders, primary immune deficiencies and Alpha 1 proteinase inhibitor deficiencies.